"A study to test how well BI 3000202 is tolerated by people with type 1 interferonopathies"

2024-514942-35-00 Protocol 1509-0003 Human pharmacology (Phase I) - Other Ongoing, recruitment ended

Start 11 Apr 2025 · Status Ongoing, recruitment ended · 6 EU/EEA countries · 14 sites · Protocol 1509-0003

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruitment ended
Participants planned 9
Countries 6
Sites 14

Type 1 interferonopathies

Key facts

Sponsor
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
11 Apr 2025 → ongoing
Decision date (initial)
2025-11-20
Transition trial
No
Low-intervention
No
Rare-disease indication
Yes
Vulnerable population
Yes

External identifiers

EU CT number
2024-514942-35-00
WHO UTN
U1111-1309-4909

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Type 1 interferonopathies

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Boehringer Ingelheim International GmbH

Sponsor organisation
Boehringer Ingelheim International GmbH
Address
Binger Strasse 173
City
Ingelheim Am Rhein
Postcode
55216
Country
Germany

Scientific contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Public contact point

Organisation
Boehringer Ingelheim International GmbH
Contact name
CT Disclosure & Data Transparency

Boehringer Ingelheim Espana S.A.

Sponsor organisation
Boehringer Ingelheim Espana S.A.
Address
Carrer Prat De La Riba 50, Sant Cugat Del Valles Sant Cugat Del Valles
City
Barcelona
Postcode
08174
Country
Spain

Locations

6 EU/EEA countries · 14 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ongoing, recruitment ended 1 1
France Ongoing, recruitment ended 2 3
Germany Ongoing, recruitment ended 2 3
Italy Ongoing, recruitment ended 1 2
Portugal Ongoing, recruitment ended 1 2
Spain Ongoing, recruitment ended 2 3
Rest of world 0

Investigational sites

Belgium

1 site · Ongoing, recruitment ended
Universitair Ziekenhuis Gent
Neurologie, Corneel Heymanslaan 10, 9000, Gent

France

3 sites · Ongoing, recruitment ended
Hopital Necker Enfants Malades
Centre d'Investigation Clinique, 149 Rue De Sevres, 75015, Paris
Assistance Publique Hopitaux De Paris
Service Médecine Interne, 4 Rue De La Chine, 75020, Paris
Centre Hospitalier Universitaire De Montpellier
Centre d’Investigation Clinique, 80 Avenue Augustin Fliche, 34295, Montpellier Cedex 5

Germany

3 sites · Ongoing, recruitment ended
Technische Universitaet Dresden
Klinik und Poliklinik für Dermatologie, Fetscherstrasse 74, Johannstadt-Nord, Dresden
Universitaetsklinikum Tuebingen AöR
Universitäts-Hautklinik, Liebermeisterstrasse 25, Innenstadt, Tuebingen
Medizinische Hochschule Hannover
Klinik für Pädiatrische Pneumologie, Allergologie und Neonatologie, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover

Italy

2 sites · Ongoing, recruitment ended
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
DSCS UO Neuropsichiatria Infantile, Piazzale Spedali Civili 1, 25123, Brescia
Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo
SC (UCO) Medicina Clinica, Via Dell' Istria 65/1, 34137, Trieste

Portugal

2 sites · Ongoing, recruitment ended
Unidade Local De Saude De Santo Antonio E.P.E.
Neurology department, Rua Dom Manuel II 57, 1508, Porto
Unidade Local De Saude De Santa Maria E.P.E.
Serviço Reumatologia, Avenida Professor Egas Moniz, 1649-035, Lisbon

Spain

3 sites · Ongoing, recruitment ended
Hospital Universitario La Paz
Reumatología Pediátrica, Paseo De La Castellana 261, 28046, Madrid
University Hospital Virgen Del Rocio S.L.
Pediatría, Avenida De Manuel Siurot S/n, 41013, Sevilla
Hospital Universitari Vall D Hebron
Unidad de enfermedades infecciosas e inmunodeficiencias, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2026-01-09 2026-01-26 2026-03-05
France 2025-06-10 2025-10-21 2026-03-05
Germany 2025-06-16 2025-08-28 2026-03-05
Italy 2025-06-27 2026-02-24 2026-03-05
Portugal 2025-11-17 2025-11-18 2026-03-05
Spain 2025-04-11 2025-07-29 2026-03-05

Application history

6 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-11-06 Germany Acceptable
2025-03-07
2025-03-07
2 SUBSTANTIAL MODIFICATION SM-1 2025-07-01 Germany Acceptable
2025-08-27
2025-08-27
3 SUBSTANTIAL MODIFICATION SM-2 2025-09-25 Germany Acceptable 2025-10-17
4 SUBSEQUENT ADDITION OF MSC APP-4 2025-10-09 Acceptable
2025-08-27
2025-11-20
5 SUBSTANTIAL MODIFICATION SM-3 2025-12-10 Germany Acceptable 2025-12-23
6 NON SUBSTANTIAL MODIFICATION NSM-1 2026-01-07 Germany Acceptable 2026-01-07